Pharmaceutical composition comprising a spiro oxathiolon/quinuclidine and method of treating senile dementia

US5106831A · kind A · utility

Assignee

• State of Israel, represented by the Prime Minister's office, Israel Institute for Biological Research CNT ILX COD 07 · IL

Inventors

• Abraham Fisher · Haifa, IL
• Ishai Karton · Nes Ziona, IL
• Eliahu Heldman · Rehovot, IL
• Yona Grunfeld · Rehovot, IL
• Aharon Levy · Beit Hanan, IL

Key dates

• Filing date: Oct 19, 1990
• Grant date: Apr 21, 1992
• Expiry date: Oct 19, 2010

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D497/20
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

A pharmaceutical composition is disclosed comprising (-)-cis-2-methylspiro(1,3-oxathiolan-5,3')quinuclidine, and/or the pharmaceutically compatible acid addition salts thereof, together with at least one of physostigmine, tetrahydroaminoacridine, choline, lecithin, piracetam, aniracetam, pramiracetam, oxiracetam, 4-aminopyridine, 3,4-diaminopyridine, somatostatin, pirenzepine, N-methylatropine, N-butylscopolamine, scopolamine, clonidine, quanfamicine and Nerve Growth Factor. Also disclosed is a method for treating senile dementia of Alzheimer's type, which comprises coadministering to a patient in need thereof an effective dose of the spiro compound together with at least one other compound selected from those listed above.